Abstract P1-10-05: A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC)

2015 ◽  
Author(s):  
George Dranitsaris ◽  
Bo Yu ◽  
Jennifer King ◽  
Adams Zhang ◽  
Satyn Kaura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis

A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer

1996 ◽  
Vol 10 (5) ◽  
pp. 504-521 ◽  
Author(s):  
Robert Launois ◽  
Jeanne Reboul-Marty ◽  
Bernadette Henry ◽  
Jacques Bonneterre
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Second Line ◽  
Utility Analysis ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals PCN12: COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER

2001 ◽  
Vol 4 (2) ◽  
pp. 88
Author(s):  
R Hauser ◽  
R Theriault ◽  
M Shepherd ◽  
K Lawson ◽  
J Wilson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document